DAIC

MAY 17, 2024

Philips’ study reveals that AI-powered ECG biomarker technology may help to identify patients with significant intermittent bradyarrhythmia, potentially improving timely diagnosis and management. ET on Friday, May 17 in the HRS Abstract area to learn more about this study and its impact on the future of cardiac care.

Heart Rhythm 52

Heart Rhythm Technology Arrhythmia Outcomes 52

CardiacWire

DECEMBER 3, 2023

Jimenez and Ali co-founded AccurKardia in 2019 with a vision for unlocking the value of the ECG signal, and the company currently markets one of the few FDA-cleared solutions for automated ECG interpretation and arrhythmia detection. Here’s the rest of their story and vision for ECG automation.

Arrhythmia 52

Arrhythmia Atrial Flutter Reimbursement Atrial Fibrillation 52

GEMMS

MAY 22, 2024

Innovative algorithms analyze gene biomarkers to provide predictive insights and personalized patient therapy. Point of Care Tests Point-of-care testing (POCT) quickly assesses cardiac biomarkers and other heart health indicators, aiding in prompt diagnosis and treatment decisions.

Heart Disease 52

Heart Disease Blood Pressure Technology Innovation 52

Frontiers in Cardiovascular Medicine

NOVEMBER 17, 2024

Coronary heart disease (CHD), with common complications including myocardial infarction, arrhythmia, heart failure, is one of the leading causes of global death. Both elevated lactate levels and decreased albumin levels may reflect the body's stress response and inflammatory reaction.

ICU 59

ICU Heart Disease Myocardial Infarction Biomarkers 59

Dr. Smith's ECG Blog

AUGUST 9, 2024

There are three mechanisms of arrhythmia: automatic, re-entry, and triggered. The most common triggered arrhythmia is Torsades de Pointes. It is a benign arrhythmia which requires no specific treatment. Possible mechanisms of ventricular arrhythmias elicited by ischemia followed by reperfusion. What is the rhythm?

Chest Pain 106

Chest Pain Arrhythmia Myocardial Infarction STEMI 106

DAIC

MARCH 7, 2024

The cohort receiving the lowest dose of 20 million cells has been initiated with no treatment-emergent adverse events, arrhythmias, rejection, or allergic response. The first author of the study is R. David Anderson , MD, Professor of Medicine at the University of Florida at Gainesville.

Heart Failure 105

Heart Failure Biomarkers Reimbursement CMS 105

Cardiometabolic Health Congress

SEPTEMBER 13, 2024

Antiphospholipid Syndrome (APS): Marco Bernardi, MD’s (Italy) presentation on cardiovascular complications in APS among older adults emphasized the challenges of current therapies and the need for safer treatments and new diagnostic biomarkers. REVERSE-FLOW Trial: Prof. ILRs may benefit BrS patients with unexplained syncope.

Hypertension 59

Hypertension Cardiovascular Disease Bicuspid/Mitral Arrhythmia 59

Frontiers in Cardiovascular Medicine

FEBRUARY 13, 2024

By comparing myocardial injury patients with non-myocardial injury patients, notable differences were observed in age, pre-existing medical conditions (e.g.,

Risk Factors 64

Risk Factors Laboratory Coronary Artery Disease Cerebrovascular Disease 64

Cardiometabolic Health Congress

AUGUST 8, 2024

Key contributions: Advanced cardiac imaging (e.g., high-sensitivity troponin, NT-proBNP) in risk stratification Utilization of advanced echocardiographic techniques (e.g.,

Education 59

Education Cardiovascular Disease Diabetes Kidney Disease 59

Open Heart

DECEMBER 7, 2023

Data were mapped based on the population assessed, cardiovascular outcomes examined, inclusion of objective measures of cardiac dysfunction such as biomarkers or cardiovascular imaging, or whether cardiovascular symptoms or patient-reported functional outcomes measures were recorded.

Article 52

Article Myocardial Infarction Cardiovascular Imaging Biomarkers 52

The British Journal of Cardiology

DECEMBER 3, 2024

Protection against the increased risk of sudden cardiac death (SCD) due to ventricular arrhythmias is offered by the implantation of cardiac defibrillators. None of the deaths were directly arrhythmia related. A life-expectancy of less than one year is usually a contraindication to the implantation of these devices.

Defibrillator 40

Defibrillator Sudden Cardiac Death Biomarkers Arrhythmia 40

DAIC

FEBRUARY 1, 2024

Elevated levels of two protein biomarkers that indicate heart damage were associated with undetected or symptomless cardiovascular disease in adults with Type 2 diabetes compared to those without Type 2 diabetes, according to new research published May 31, 2023, in the Journal of the American Heart Association, JAHA. .**

Cardiovascular Disease 104

Cardiovascular Disease Atherosclerosis Strokes Stroke 104

Open Heart

AUGUST 16, 2023

Objective To characterise cardiac remodelling, exercise capacity and fibroinflammatory biomarkers in patients with aortic stenosis (AS) with and without diabetes, and assess the impact of diabetes on outcomes. Secondary endpoint was all-cause death.

Exercise 52

Exercise Diabetes Stenosis Aortic 52

Frontiers in Cardiovascular Medicine

DECEMBER 11, 2024

BackgroundCardiovascular biomarkers are crucial for monitoring cancer therapy-related cardiac toxicity, but the effects on early stage are still inadequate. According to whether arrhythmia occurred, patients were divided into two groups (healthy group or arrhythmias group), and basic clinical characteristics were collected and compared.

Arrhythmia 52

Arrhythmia Cancer Biomarkers Research 52

Frontiers in Cardiovascular Medicine

FEBRUARY 20, 2025

BackgroundMyocardial fibrosis (MF) is a prevalent pathological condition associated with various heart diseases, such as heart failure and arrhythmias, which disrupt electrical signals and reduce pumping efficiency. This research explored the therapeutic effects and potential mechanisms of Ligustrum vicaryi L.

Pharmacology 40

Pharmacology Atherosclerosis Biomarkers Cancer 40